Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.56
| Quarter | EPS | Revenue (EUR) | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 13, 2026 | -0.04 | -0.13 | Miss -225.0% | — | €150.75M | €145.85M | -3.3% | 1D Pre+4.3% | On-Day-7.8% | 1D Post-3.0% |
Q ended Mar 31, 2026 Reported Apr 8, 2026 | -0.17 | -0.34 | Miss -100.0% | — | €162.7M | €159.22M | -2.1% | 1D Pre-1.5% | On-Day+4.3% | 1D Post-2.6% |
Q ended Dec 31, 2025 Reported Dec 31, 2025 | 0.07 | 0.04 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar or period for exact figures. Values as reported; not adjusted for splits after the report date.
| Miss -42.9% |
| — |
| €265.56M |
| €253.27M |
| -4.6% |
| 1D Pre-1.0% |
| On-Day-1.3% |
| 1D Post+3.2% |
Q ended Sep 30, 2025 Reported Nov 5, 2025 | -0.07 | -0.04 | Beat +42.9% | — | €191.66M | €163.89M | -14.5% | 1D Pre-1.2% | On-Day-15.7% | 1D Post-1.2% |